Loading

Our Team

Developing Innovative Drugs and Drug Combinations to Improve Clinical Outcomes in Advanced Cancer

Research Portfolio

Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive┬« (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Market Demand

The numbers behind our research define Validive and camsirubicin opportunities

Investment Opportunities

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Validive┬« (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of chemoradiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.

Product Indications Preclinical Phase 1 Phase 2 Phase 3 Status

Validive®

Radiation induced SOM in OPC

Preclinical complete

Phase 1 complete

Phase 2 in progress

Phase 3 not started

Completed Phase 2 Trial, Phase 2b/3 starting H2 2020

Camsirubicin

Advanced Soft Tissue Sarcoma

Preclinical complete

Phase 1 complete

Phase 2 in progress

Phase 3 not started

Completed Phase 2 in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2

MNPR-101

Severe COVID-19

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Collaboration with NorthStar for severe COVID-19

MNPR-101

Advanced Solid Cancers

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Pre-IND